Joseph McCracken

Joseph S.
McCracken currently works at REGiMMUNE Corp., as Director from 2015, Neuropore Therapies, Inc., as Director from 2019, Modalis Therapeutics Corp., as Director from 2018, Savara, Inc., as Lead Independent Director from 2019, and Eos Therapies, Inc., as Director.
Dr. McCracken also formerly worked at NewLink Genetics Corp., as Director, Aravas, Inc., as Director, Calliditas Therapeutics Suisse SA, as Director, Kindred Biosciences, Inc., as Independent Director from 2018 to 2021, Nexvet Biopharma Plc, as Independent Non-Executive Director from 2014 to 2017, Nexvet Australia Pty Ltd., as Director from 2014 to 2015, Calliditas Therapeutics France SAS, as Director, Lumos Pharma, Inc., as Independent Director from 2020 to 2024, Alkahest, Inc., as Director from 2013 to 2020, Genentech, Inc., as Vice President-Business Development from 2000 to 2009, Roche Pharmaceuticals, Inc., as VP, Global Head-Business Development & Licensing from 2011 to 2013, Aventis Pharmaceuticals, Inc., as Vice President-Business Development, Hoffmann-La Roche, Inc., as VP, Global Head-Business Development & Licensing in 2013, Roche Diagnostics KK, as General Manager from 2009 to 2011, and Rhone-Poulenc Rorer SA, as Vice President-Business Development from 1997 to 2000.
Dr. McCracken received his undergraduate degree in 1976, graduate degree in 1977, and doctorate degree in 1980 from The Ohio State University.